Nu Skin Enterprises has bolstered its financial position by completing a significant refinancing package. The move provides the wellness and beauty company with fresh capital intended to support its ongoing strategic restructuring and leadership transition, with a pronounced focus on advancing its technological initiatives.
Leadership and Strategic Pivot Amid Financial Restructuring
The refinancing coincides with a period of executive changes at Nu Skin. The company has appointed Chelsea Lantz as its interim Chief Financial Officer and named Chayce Clark to lead its operational divisions. Strategically, management is placing considerable emphasis on its connected device, the “Prism iO” smart wellness system. The goal is to deploy over 100,000 units of this hardware by the end of the year, aiming to establish a recurring revenue stream through associated digital subscriptions.
To fund this transformation and other corporate needs, Nu Skin finalized a new credit agreement on March 27. The package consists of a $175 million term loan and a $75 million revolving credit facility, each with a five-year maturity. According to the company, the term loan was fully drawn at closing to repay existing bank debt.
Lender Covenants and Market Performance
The new financing is not without constraints. Lenders have attached strict covenants to the agreement, requiring Nu Skin to maintain a leverage ratio of consolidated debt to operating income of no more than 2.25 to 1.00. This condition is designed to ensure the company preserves a stable balance sheet as it invests in its market expansion. Interest rates on the debt are pegged to the SOFR benchmark, plus a margin that adjusts based on the company’s leverage level.
Should investors sell immediately? Or is it worth buying Nu Skin?
The company’s recent operational challenges are reflected in its stock performance. Shares closed at €6.25 on Friday, hovering just above a yearly low of €6.15. Market technicians note that the Relative Strength Index (RSI) reading of nearly 30 indicates the stock is in technically oversold territory, highlighting the significant selling pressure experienced over the preceding 30-day period.
Financial Targets and Upcoming Milestones
Looking ahead, Nu Skin’s management has provided financial guidance for the full year 2026, forecasting revenue in a range between $1.35 billion and $1.50 billion. This outlook incorporates an estimated negative foreign currency impact of up to $15 million.
Key upcoming milestones for investors include:
- May 6, 2026: Anticipated release of first-quarter financial results.
- Q1 2026 Revenue Forecast: Projected to be between $320 million and $340 million.
- Q1 2026 Adjusted EPS Forecast: Expected to range from $0.10 to $0.20 per share.
- Prism iO Unit Goal: Target to place over 100,000 units by year-end.
The upcoming quarterly reports will be scrutinized to determine if the newly secured liquidity is sufficient to accelerate growth in emerging markets and fund the expansion of the company’s digital data platform. Given that the first quarter is typically a seasonally softer period, market participants are expected to focus intently on the growth trajectory anticipated for the second half of the year.
Ad
Nu Skin Stock: Buy or Sell?! New Nu Skin Analysis from March 29 delivers the answer:
The latest Nu Skin figures speak for themselves: Urgent action needed for Nu Skin investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 29.
Nu Skin: Buy or sell? Read more here...
